In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y.

Authors

• Anthony Donato, Reading Hospital/Tower Health, West Reading, Pennsylvania, USAFollow

Document Type

Article

Publication Date

3-2026

Abstract

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Publication Title

Annals of internal medicine

Volume

179

Issue

3

First Page

26

Last Page

26

Recommended Citation

Donato, A. (2026). In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y.. Annals of internal medicine, 179 (3), 26-26. https://doi.org/https://doi.org/10.7326/annals-25-05604-jc